Project Grant R00HL177822
Award Date
4/18/25
Completion Date
3/31/28
Dollars Obligated
$395K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Palo Alto, CA 94304, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will fund research into a novel immunocytokine therapy to promote immune tolerance in hemophilia. The $1,165,276 award to the Trustees of Indiana University in Indianapolis will support preclinical assessments of the F5111-IC biotherapeutic, which aims to suppress the formation of inhibitor antibodies that can complicate standard clotting factor...
This $685,621 Project Grant awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a comprehensive, multi-year study to identify genetic and environmental factors underlying the high incidence of factor VIII inhibitors in hemophilia A patients of Mexican descent. The research team at the University of Texas Rio Grande Valley will recruit and extensively characterize a cohort of 200 severe hemophilia A patients with Mexican ancestry,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Grant Program (CFDA 93.837), provides $107,948 in funding to The Leland Stanford Junior University (Stanford University) to engineer hematopoietic stem and progenitor cells (HSPCs) to produce B cells that secrete anti-PCSK9 antibodies. The goal is to develop an effective and durable treatment for hypercholesterolemia, a major public health issue. The project aims to:...
This $386,000 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program will support the development of chemical modulators to target the BCL11A protein and induce fetal hemoglobin production. The research aims to create proximity-based protein degradation tools, such as proteolysis targeting chimeras (PROTACs) and molecular glues, that can deplete BCL11A and reactivate fetal hemoglobin as a potential treatment...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $159,512 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Leland Stanford Junior University, also known as Stanford University. The grant supports research to investigate the role of the unfolded protein response in genetic dilated cardiomyopathy, a leading cause of heart failure. The project will utilize induced pluripotent stem cell-derived cardiomyocytes carrying DCM mutations to study the...
This $493,810 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research to investigate the cellular interactions and programming of hematopoietic stem and progenitor cells (HSPCs) in zebrafish and mouse models. The research aims to 1) determine the role of vascular endothelial growth factor C (VEGFC) in the release and fate determination of HSPCs from the hemogenic endothelium, and 2)...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), provides USD $117,804 to The Leland Stanford Junior University to investigate the role of macrophages and T-cell recruitment in immune checkpoint inhibitor (ICI)-induced myocarditis. The project aims to characterize the mechanistic effects of blocking the CXCR3 receptor and its ligands CXCL9/10 on macrophage-mediated T-cell migration...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $151,523 to investigate the role of fibrinogen in regulating thromboinflammation in acute and chronic venous thrombosis. The 5-year project aims to use novel RNA therapy with small interfering RNA (siRNA) delivered via lipid nanoparticles to selectively reduce circulating fibrinogen levels. Researchers at The Medical College of Wisconsin,...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $784,206 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Albert Einstein College of Medicine in Bronx, NY. The 4-year grant, active from December 2024 to November 2028, will support research to investigate the role of the CSF-1/CSF-1R axis in cardiac repair and remodeling after myocardial infarction. The project aims to examine the in vivo effects of macrophage-specific CSF-1R activation, the role...
This $213,284 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the regulation of endothelial hemoglobin alpha (HBA) by iron homeostasis. The overarching goal is to elucidate the molecular mechanisms by which systemic iron levels modulate endothelial function, a key factor in cardiovascular diseases. The research will leverage mouse models of iron overload and...